Method of treating cardiac arrhythmia with long acting atrial natriuretic peptide(LA-ANP)

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Mayo Foundation For Medical Education And Research, , University Of Iowa Research Foundation patent solves the following problem:

Natriuretic peptides and polypeptides that can cause natriuresisincreased sodium excretion in the urine. Such polypeptides can be produced in the brain, heart, kidney, and / or vascular tissue. The natriuretic polypeptide family man include cardiac hormone atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and urodilatin (uro). Natriuretic peptides act by well-described guanylyl cyclase receptor (ie, NPR-A to ANP, BNP, and uro, and NPR-B for CNP). And the second messenger cyclic 35 guanosine monophosphate (cGMP) (Kuhn (2003) Circ Res. 93 :. 700-709; Tawaragi et al (1991) Biochem Biophys Res Commun 175: …. 645-651, and Komatsu et al (1991) Endocrinol 129: 1104-1106) …

Our analysis of this patent is as follows:

Mayo Foundation For Medical Education And Research, , University Of Iowa Research Foundation’s patent US 9193777 B2 deals with Method of treating cardiac arrhythmia with long acting atrial natriuretic peptide(LA-ANP).
Materials and Methods related to making and using natriuretic peptides with a mutation that results in an extended carboxy terminal.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

T cell receptors specific for immunodominant CTL epitopes of HCV

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Tripep Ab patent solves the following problem:

Since the recognition of HCV in 1989, it is now estimated that 180 million individuals are infected worldwide and 130 million are chronic HCV carriers at risk of developing liver cirrhosis and / or liver cancer . See Kantzanou, M., et al. (2003) viral escape and T cell exhaustion in hepatitis C virus infection analyze the use of Class I peptide tetramer, Immunol Lett 85: 165-71, which is included in the discussion in its entirety. A small enveloped RNA viruses, HCV is one of the most continue to poison people. The natural resolution of HCV infection occurs in a minority of infected individuals. See Alter, H. 2006. viral hepatitis. Hepatology 43: S230-4, which included the reference in its entirety. Because of the continued increase of reported incidents in Europe and the fact that the current interferon therapy only 50-60% effective, a decline in HCV prevalence was expecting in the near future. Some promising HCV specific inhibitor designed to prevent the protease / polymerase activity in HCV non-structural proteins (NS) 3-5 currently in clinical evaluation. See Kronenberger, B., and S. Zeuzem, (2009) Current and future treatment options for HCV. Ann Hepatol 8: 103-12, which is included in the discussion in its entirety.

Our analysis of this patent is as follows:

Tripep Ab’s patent US 9193778 B2 deals with T cell receptors specific for immunodominant CTL epitopes of HCV.
The present invention relates generally to the field of immunology. Particularly, the invention concerns the discovery of certain T cell receptors (TCRs) specific for an immunodominant CTL epitope of hepatitis C virus (HCV). Embodiments include TCRs, DNAs encoding TCRs, ways to make TCRs, and methods of using TCRs to treat, prevent or inhibit hepatitis C virus (HCV) growth.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Medimmune, Llc patent solves the following problem:

ICOS is a type I transmembrane proteins that contain an extracellular (Ig) V-like domain. ICOS serves as the receptor for B7h co-stimulatory molecules. ICOS expression is under the temple of human T cells and was upregulated in the hours after TCR engagement. ICOS expression continue to activate T cells subpopulations such as Th1, Th2, and Th17 CD4 + cells.

Our analysis of this patent is as follows:

Medimmune, Llc’s patent US 9193789 B2 deals with Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease.
The present invention provides anti-human ICOS antibody with increased effector function. invention further relates to pharmaceutical compositions, immunotherapeutic composition, and methods of using therapeutic antibody that binds to human ICOS antigen and mediate ADCC, CDC, and / or antibody-dependent phagocytosis (opsonization) for the treatment and control of T cell-mediated diseases and disorders, such as, but not limited to, chronic infections, autoimmune diseases or disorders, inflammatory diseases or disease, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Combined hairpin-antisense compositions and methods for modulating expression

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Brookhaven Science Associates, Llc patent solves the following problem:

Antisense suppression aimed at sealing an antisense strand of a nucleic acid in a gene or mRNA, thus preventing expression of the gene or mRNA translation. Usually for antisense suppression, an expression cassette is designed to express an RNA molecule complementary to all or part of an mRNA encoding a target. Over-expression of the antisense RNA molecule can result in reduced expression of the native gene.

Our analysis of this patent is as follows:

Brookhaven Science Associates, Llc’s patent US 9193972 B2 deals with Combined hairpin-antisense compositions and methods for modulating expression.
A nucleotide make comprising a nucleotide sequence that forms a stem and a loop, where the loop comprising a nucleotide sequence that modulates expression of a target, wherein the stem comprising a nucleotide sequence that modulates expression of a target, and where the target modulated nucleotide loop and the target modulated on the nucleotide sequences of the stem can like or race. Vector control methods target expression, by providing a cell, and methods of treating conditions comprising the nucleotide is expressed.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer

File for Quick & Easy Patent Protection with PowerPatent.

The Raadysan Biotech, Inc. patent solves the following problem:

Breast cancer accounts for 18% of all cancers in women, making it the leading cause of cancer-related death in women (McPherson K et al (2000) BMJ 321 (7261): 624 -8). In the meantime, routine mammography is the most commonly used method for early detection of breast cancer (Smith RA et al (2012) Oncology 26 (5): 471-5, 479-81, 485-6). Therefore, early diagnosis and treatment of breast cancer, which play a major role in reducing the death (Misek DE and Kim EH (2011) Int J Proteomics 2011: 343582). Most of the drugs available for the treatment of breast cancer target growth factors and endocrine receptor, especially the endocrine (estrogen; ER) or growth factor ((erbB-1, erbB-2 in human skin growth factor receptor 2; HER2], erbB -3 and erbB-4) receptor for the therapy (Normanno N et al (2009) Endocr Relat Cancer 16 (3): 675-702).

Our analysis of this patent is as follows:

Raadysan Biotech, Inc.’s patent US 9193970 B1 deals with Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer.
The present disclosure relates generally to cancer and especially breast cancer with estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and the diagnostic methods and resilient, and therapeutic intervention, including copying things P 40 (RFC40). Methods and assays to evaluate breast cancer given. disclosure also relates to restrictions or modulation RFC40 treatment or alleviation of cancer, including breast cancer. RFC40 inhibitor, including siRNAs and miRNAs, specifically affect cancer cells, especially breast cancer cells, was given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Audio processing based on changed position or orientation of a portable mobile electronic apparatus

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Nokia Technologies Oy patent solves the following problem:

Our analysis of this patent is as follows:

Nokia Technologies Oy’s patent US 9196238 B2 deals with Audio processing based on changed position or orientation of a portable mobile electronic apparatus.
An apparatus comprising at least one processor and at least one memory including computer program code for at least one memory and the computer program code configured to, with the at least one processor , cause the apparatus at least to do to determine a change in position and / or orientation of a tool, and processing at least two audio signal depending on the change in position and / or orientation of the building at least one output signal processing where the two audio signal dependent on changes in position and / or orientation of the output signal containing a representation of acoustic energy from a first direction.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Markers of acute myeloid leukemia stem cells

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The The Board Of Trustees Of The Leland Stanford Junior University patent solves the following problem:

Basic cancer research has focused on identifying the genetic changes that lead to cancer. This has led to major advances in our understanding of the molecular and biochemical pathways involved in tumorigenesis and malignant transformation. However, our understanding of cellular biology impaled. Although the effects of specific mutations on proliferation and security model cells, such as fibroblasts or cell lines, can be predicted, the effect of these mutations on actual cells involved in certain types of most cancer charade.

Our analysis of this patent is as follows:

The Board Of Trustees Of The Leland Stanford Junior University’s patent US 9193955 B2 deals with Markers of acute myeloid leukemia stem cells.
Points acute myeloid leukemia stem cells (AMLSC) recognized. The points were differentially expressed compared to normal counterpart cells, and is useful as a diagnostic and therapeutic target.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Bracco Suisse S.A. patent solves the following problem:

Diagnostic imaging agents can use to improve images obtained different imaging techniques (known as contrast agent or enhancing agent) to be a widely adopted practice in the diagnostic field.

Our analysis of this patent is as follows:

Bracco Suisse S.A.’s patent US 9192685 B2 deals with Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same.
Pharmaceutical kit comprising (i) a target building containing a target ligand and an anti-polymer antibody and (ii) a polymer-containing liposome or gas-filled microvesicle able to bind or association said making. Also disclosed are methods of preparing and administering the said society, as well as a community building comprising said target and said liposome or gas-filled microvesicle.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method and apparatus for integrated circuit mask patterning

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Taiwan Semiconductor Manufacturing Company, Ltd. patent solves the following problem:

The semiconductor integrated circuit (IC) industry is experiencing rapid growth. In the course of IC evolution, functional density (ie, the number of interconnected devices per chip area) general increased while geometry size (ie, at least a component (or lines) that can be created using a fabrication process) declined. This process generally provides benefits by increasing production efficiency and lowering associated costs. The cuts also increased the complexity of the processing and manufacturing ICs and, with these growth realized, similar events in IC manufacturing requirements.

Our analysis of this patent is as follows:

Taiwan Semiconductor Manufacturing Company, Ltd.’s patent US 9195134 B2 deals with Method and apparatus for integrated circuit mask patterning.
If an integrated circuit (IC) design method. method includes receiving a IC design layout, design the layout of a first main section, and add a negative assist the design Layout, where the negative help of one a first width, the negatives with the help of dividing the first main part to a second first part and a third who first phase of breadth, and the first broad sub-resolutions photolithography process.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

HCV antigen-antibody combination assay and methods and compositions for use therein

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Abbott Laboratories patent solves the following problem:

According to WHO statistics, as many as 170 million people worldwide are infected with hepatitis C virus (HCV), a viral infection of the liver. 75 to 85% of people infected with HCV progress to chronic infection, approximately 20% of cases develop complications of chronic hepatitis C, including liver cirrhosis or hepatocellular carcinoma after 20 years of infection. The current recommended treatment for HCV infection is a combination of interferon and ribavirin drugs, but the treatment is not effective in all cases and liver transplantation showed hepatitis C-related end-stage liver disease. At present, there is no vaccine available to prevent HCV infection, so all precautions to avoid infection should be removed.

Our analysis of this patent is as follows:

Abbott Laboratories’s patent US 9194873 B2 deals with HCV antigen-antibody combination assay and methods and compositions for use therein.
The present invention generally relates to the combination immunoassays, reagents and kits for the simultaneous detection of HCV antigens and anti-HCV antibody in a test sample.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.